Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBiomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
55.84 USD -1.60 ( 2.79%)
Last update at 2026-11-03T20:54:00Z
VOLUME
3458750
Market Cap
10504.70M
P/E
30.51

Momentum Score

…

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
52.00
Low
56.32
High
52 Week Price Range
50.76
Low
66.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioMarin Pharmaceutical develops and commercializes therapies for rare genetic diseases, focusing on enzyme replacement, small-molecule, and gene therapy approaches. Its long-term growth could be driven by uptake of approved therapies, advancement of late-stage gene therapy candidates, and geographic expansion of specialty care access, which may benefit from durable demand in ultra-rare indications.
The company faces material clinical and regulatory risk from its pipeline, pricing and reimbursement pressure in specialty markets, and execution and manufacturing risks that could affect approvals and commercialization.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
57.44
Dividend Yield
-
Revenue TTM
3221.25M
Revenue Per Share
16.80
Gross Profit TTM
1701.09M
Debt / Equity
0.11
ROE
5.94%
Net Debt
-668.81M
ROCE
7.22%
Diluted EPS TTM
1.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 482.48M 541.76M 188.56M 149.58M -75.35M
Net income 348.90M 426.86M 167.65M 141.56M -64.08M
Selling general administrative 1153.02M 532.30M 404.00M 403.71M 354.30M
Selling and marketing expenses 124.00M 476.70M 488.40M 450.30M 405.10M
Gross profit 2484.43M 2273.68M 1887.16M 1612.37M 1375.76M
Reconciled depreciation 79.56M 96.43M 102.08M 101.97M 108.04M
Ebit 493.38M 554.10M 202.39M 57.55M -60.01M
Ebitda 572.94M 650.53M 306.77M 159.51M 48.03M
Depreciation and amortization 79.56M 96.43M 104.39M 101.97M 108.04M
Non operating income net other - - - - 10.48M
Operating income 533.48M 484.21M 185.77M 57.55M -60.01M
Other operating expenses 2687.78M 2369.70M 2233.45M 2054.48M 1928.62M
Interest expense 10.90M 12.67M 17.34M 15.97M 15.34M
Tax provision 133.58M 114.90M 4.66M 8.02M -11.27M
Interest income 74.90M 74.88M 49.01M 18.03M 10.48M
Net interest income 64.00M 62.15M 34.14M 2.06M -4.86M
Income tax expense 133.58M 114.90M 20.92M 8.02M -11.27M
Total revenue 3221.25M 2853.91M 2419.23M 2096.04M 1846.28M
Total operating expenses 1950.95M 1789.47M 1701.39M 1570.81M 1458.10M
Cost of revenue 736.83M 580.24M 532.06M 483.67M 470.51M
Total other income expense net -51.00M 57.55M 2.79M 92.03M -15.34M
Net income from continuing ops 348.90M 426.86M 147.02M 141.56M -64.08M
Net income applicable to common shares - - - 141.56M -64.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7594.02M 6988.94M 6841.60M 6375.07M 6003.32M
Intangible assets 213.84M 255.28M 294.70M 338.57M 388.65M
Other current assets 185.78M 201.53M 141.39M 104.52M 110.44M
Total liab 1507.02M 1330.95M 1890.05M 1771.92M 1732.59M
Total stockholder equity 6087.00M 5657.99M 4951.55M 4603.16M 4270.74M
Other current liab 437.58M 334.58M 354.24M 346.56M 329.40M
Common stock 0.19M 0.19M 0.19M 0.19M 0.18M
Capital stock 0.19M 0.19M 0.19M 0.19M 0.18M
Retained earnings 154.21M -194.69M -621.55M -789.20M -925.69M
Other liab - - - 73.50M 113.69M
Good will 196.20M 196.20M 196.20M 196.20M 196.20M
Other assets - - - 1604.19M 1600.84M
Cash 1311.68M 942.84M 755.13M 724.53M 587.28M
Total current liabilities 759.03M 606.99M 1177.02M 588.88M 539.82M
Current deferred revenue - 1.37M 4.62M 0.71M 6.96M
Net debt -668.81M -293.38M 378.75M 358.49M 491.80M
Short term debt 8.69M 23.07M 502.66M 10.38M 10.46M
Short long term debt - - 493.88M - -
Short long term debt total 642.87M 649.47M 1133.88M 1083.02M 1079.08M
Other stockholder equity 5956.58M 5790.84M 5611.56M 5396.04M 5181.81M
Property plant equipment - - - 1114.32M 1035.46M
Total current assets 3953.49M 3232.43M 2956.09M 2751.46M 2274.39M
Long term investments 492.24M 521.24M 611.13M 333.83M 507.79M
Net tangible assets - - - 4068.39M 3685.89M
Short term investments 248.93M 194.86M 318.68M 567.01M 426.60M
Net receivables 908.21M 660.53M 633.70M 461.32M 373.40M
Long term debt 597.18M 595.14M 593.10M 1083.02M 1079.08M
Inventory 1298.88M 1232.65M 1107.18M 894.08M 776.67M
Accounts payable 312.77M 235.40M 315.51M 231.24M 193.00M
Accumulated other comprehensive income -23.98M 61.65M -38.65M -3.87M 14.43M
Common stock total equity - - - - 0.18M
Retained earnings total equity - - - - -925.69M
Non currrent assets other 277.05M 251.39M 121.22M 176.24M 151.76M
Non current assets total 3640.53M 3756.51M 3885.51M 3623.62M 3728.94M
Capital lease obligations 8.69M 7.57M 8.78M 10.38M 10.46M
Long term debt total - - - - 1079.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -18.07M 136.49M -100.99M -20.03M -366.31M
Change to liabilities - - - 59.02M 12.35M
Total cashflows from investing activities -414.24M 136.49M -111.24M -20.03M -366.31M
Net borrowings 0.00M -494.99M 0.00M -2.60M -3.04M
Total cash from financing activities -42.39M -526.45M -18.73M -18.65M -0.05M
Change to operating activities - - - -5.10M 19.83M
Net income 348.90M 426.86M 167.65M 141.56M -64.08M
Change in cash 368.84M 187.72M 30.60M 137.25M -61.88M
Begin period cash flow 942.84M 755.13M 724.53M 587.28M 649.16M
End period cash flow 1311.68M 942.84M 755.13M 724.53M 587.28M
Total cash from operating activities 827.99M 572.84M 159.26M 175.90M 304.54M
Depreciation 79.56M 96.43M 104.39M 101.97M 108.04M
Other cashflows from investing activities -7.94M -0.85M -10.92M 103.33M -24.64M
Change to inventory 119.21M -63.53M -157.06M -68.26M -35.06M
Change to account receivables -228.05M -57.91M -190.44M -82.03M 65.57M
Sale purchase of stock - -77.56M -76.32M 0.00M 49.19M
Other cashflows from financing activities -42.39M -31.46M -85.79M -16.05M 2.99M
Change to netincome - - - 28.75M 185.24M
Capital expenditures 103.04M 97.42M 96.69M 131.54M 119.22M
Change receivables - - - - 65.57M
Cash flows other operating - - - - 23.17M
Exchange rate changes - - - - -0.06M
Cash and cash equivalents changes - - - - -61.88M
Change in working capital -108.68M -216.40M -336.54M -96.38M 66.03M
Stock based compensation 181.41M 201.57M 207.10M 196.31M 197.26M
Other non cash items 278.07M 8.29M 61.65M -115.47M 12.89M
Free cash flow 724.96M 475.42M 62.57M 44.36M 185.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BMRN
Biomarin Pharmaceutical Inc		 -1.60
2.79%		 55.84 30.51 10.81 3.26 1.73 2.96 16.67
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

770 Lindaro Street, San Rafael, CA, United States, 94901

415 506 6700

https://www.biomarin.com

3221

Name Title Year Born
Mr. Jean-Jacques Bienaime M.B.A., MBA Chairman & CEO 1953
Mr. Brian R. Mueller Exec. VP of Fin. & CFO 1974
Dr. C. Greg Guyer Ph.D. CTO and Exec. VP of Global Manufacturing & Technical Operations 1962
Mr. Jeffrey Robert Ajer Exec. VP & Chief Commercial Officer 1962
Dr. Henry J. Fuchs M.D., Ph.D. Pres of Worldwide R&D 1958
Ms. Erin Burkhart Group VP & Chief Accounting Officer NA
Traci McCarty VP of Investor Relations NA
Mr. George Eric Davis Exec. VP, Gen. Counsel & Sec. 1971
Mr. Philip Lo Scalzo Sr. VP & Chief Compliance Officer NA
Ms. Humaira Serajuddin Sr. VP & Chief Marketing Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…